Morgan Stanley upgraded Doximity (DOCS) to Overweight from Equal Weight with a price target of $65, up from $62. The firm says the stock’s underperformance “is at odds” with its checks on the business and strengthening platform engagement. Doximity’s guidance and Street estimates look conservative, the analyst tells investors in a research note. Morgan Stanley sees an attractive entry point at current share levels.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DOCS:
- Shifting Pharmaceutical Advertising Trends Favor Doximity: Buy Rating Justified
- Doximity initiated with an Overweight at Barclays
- Nvidia resumed, Palo Alto downgraded: Wall Street’s top analyst calls
- Doximity: Strong Growth Potential and Attractive Valuation Amid Share Price Pullback
- Doximity upgraded to Strong Buy from Outperform at Raymond James